Stereotactic radiotherapy reduces treatment costs while improving overall survival and local control in comparison to standard fractionated radiation therapy in patients with medically inoperable non-small-cell lung cancer.
That is the message from American researchers who monitored the responses of 86 patients with the disease.
The former treatment was found to be less expensive and improved survival rates, with 71% of patients surviving for 36 months, as opposed to 42%.
- Lanni, Thomas B. Jr MBA; Grills, Inga S. MD; Kestin, Larry L. MD; Robertson, John M. MD. Stereotactic Radiotherapy Reduces Treatment Cost While Improving Overall Survival and Local Control Over Standard Fractionated Radiation Therapy for Medically Inoperable Non-Small-Cell Lung Cancer. American Journal of Clinical Oncology (2011) 34: 494-498. Published October 2011.